{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"134.00","value":"34.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Duration of complete response is defined as the number of days from the first day of of corrected serum calcium ≤ 10.8 mg/dL (2.7 millimoles/L) to the last day of corrected serum calcium ≤ 10.8 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 10.8 mg/dL after the complete response. If a participant had no CSC assessment after the complete response, duration of complete response was set to zero and censored. Duration of complete response was summarized for participants who achieved a complete response using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","id":"OG000","title":"Denosumab"}],"paramType":"MEDIAN","populationDescription":"Participants with a complete response in the Response Analysis Subset","reportingStatus":"POSTED","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","title":"Duration of Complete Response","type":"SECONDARY","unitOfMeasure":"days"}